Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.
Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dalle S, Besse B, Laghouati S, Soria JC, Mateus C, Robert C, Lanoy E, Marabelle A, Lambotte O. Danlos FX, et al. Among authors: aspeslagh s. Eur J Cancer. 2018 Mar;91:21-29. doi: 10.1016/j.ejca.2017.12.008. Epub 2018 Jan 10. Eur J Cancer. 2018. PMID: 29331748
Immuno-oncology-101: overview of major concepts and translational perspectives.
Allard B, Aspeslagh S, Garaud S, Dupont FA, Solinas C, Kok M, Routy B, Sotiriou C, Stagg J, Buisseret L. Allard B, et al. Among authors: aspeslagh s. Semin Cancer Biol. 2018 Oct;52(Pt 2):1-11. doi: 10.1016/j.semcancer.2018.02.005. Epub 2018 Feb 8. Semin Cancer Biol. 2018. PMID: 29428479 Review.
Cancer immunotherapy-associated hypophysitis.
Solinas C, Porcu M, De Silva P, Musi M, Aspeslagh S, Scartozzi M, Willard-Gallo K, Mariotti S, Saba L. Solinas C, et al. Among authors: aspeslagh s. Semin Oncol. 2018 Jun;45(3):181-186. doi: 10.1053/j.seminoncol.2018.09.002. Epub 2018 Oct 21. Semin Oncol. 2018. PMID: 30352754 Review.
Bilateral Corneal Perforation in a Patient Under Anti-PD1 Therapy.
Ramaekers A, Aspeslagh S, De Brucker N, Van Mierlo C, Ten Tusscher M, Schauwvlieghe PP, Termote K. Ramaekers A, et al. Among authors: aspeslagh s. Cornea. 2021 Feb 1;40(2):245-247. doi: 10.1097/ICO.0000000000002490. Cornea. 2021. PMID: 33395118
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S, Martínez-Vila C, Wallace R, Bhave P, Reijers ILM, Thompson N, Vanella V, Gerard CL, Aspeslagh S, Labianca A, Khattak A, Mandala M, Xu W, Neyns B, Michielin O, Blank CU, Welsh SJ, Haydon A, Sandhu S, Mangana J, McQuade JL, Ascierto PA, Zimmer L, Johnson DB, Arance A, Lorigan P, Lebbé C, Carlino MS, Sullivan RJ, Long GV, Menzies AM. Owen CN, et al. Among authors: aspeslagh s. Ann Oncol. 2021 Jul;32(7):917-925. doi: 10.1016/j.annonc.2021.03.204. Epub 2021 Mar 30. Ann Oncol. 2021. PMID: 33798657 Free article.
81 results